BOSTON & GENEVA--(BUSINESS WIRE)--PHT Corporation will convene pharmaceutical research innovators at the 2014 PRO & eCOA Congress, the premier patient reported outcome (PRO) and eClinical outcome assessment meeting, March 11-13 in Boston. PHT is the leading provider of technologies used to collect patient-driven eData for clinical research.
The PRO & eCOA Congress is an exclusive educational event for sponsors focused on the science, technologies and regulatory requirements of PROs and eCOAs. It is attended by professionals in clinical operations, outsourcing, data management, eClinical technologies, regulatory affairs, and health outcomes as well as industry thought leaders, regulators and sites.
The clinical trials industry faces a very challenging operating environment characterized by inefficiency, rising costs and smaller market opportunities post launch. Keynote speaker Kenneth A. Getz’s presentation, “The New Norm for Global Clinical Trials: Patient-Centric Engagement and Participation” will discuss the importance of patient-centric and patient directed participation in clinical trials. Compelling opportunities to leverage patient centricity in key areas including protocol design and outcome measurement will be discussed. This session will also highlight lessons learned from patient-centric strategies and tactics that have been implemented during the past 18 months.
Ken Getz is the director of sponsored research programs at the Center for the Study of Drug Development, Tufts University School of Medicine and the founder and chairman of the Center for Information and Study on Clinical Research Participation (CISCRP), a non-profit organized to educate and inform patients and the public about the role that clinical research plays in advancing public health. He said, "I'm delighted to join the PRO & eCOA Congress this year to discuss and learn about the changing R&D paradigm and the critical need to engage patients as partners in pre- and post-approval studies."
Additional confirmed speakers include representatives from Biogen Idec, Celgene Corporation, Palatin Technologies, QualityMetric Inc. and PHT. The complete agenda is available on-line. Event sponsors include Bluebird Inc., Lionbridge Life Sciences, Intel and Dell.
Sheila Rocchio, MBA, PHT Vice President of Marketing and Product Management, said, “The PRO & eCOA Congress is where significant advances in eClinical research begin, as pharma, key opinion leaders, scientists and regulators share successes, opportunities and issues in adopting eCOA technologies. Join us to get firsthand knowledge about regulatory insights, lessons learned, emerging eCOA technology, and to network with colleagues and industry leaders.” Learn more about the PRO & eCOA Congress in one minute: bit.ly/10390pi
Register for the 2014 PRO & eCOA Congress at bit.ly/16EYVSg. Meet PHT at any US exhibited event by March 2014 and enter to win free registration and a two night stay at the Taj Hotel, Boston: bit.ly/PHTEvents. PHT invites all Congress alumni to join the PRO & eCOA Congress LinkedIn Community to exchange information, ideas and experiences throughout the year.
About PHT Corporation
PHT Corporation helps pharmaceutical companies and CROs conduct clinical trial programs with greater confidence, ease and accuracy. Proven PHT electronic clinical outcome assessment (eCOA) Systems collect patient-driven eData via smartphones, tablets and the web. This data, available via StudyWorks™ online reporting portal, provides sponsors and clinicians with a real time window into how patients feel and function. PHT has helped trial sponsors collect patient-driven eData in 660+ global trials resulting in 16+ regulatory approvals. PHT Clinical Science and Consulting offers the scientific, regulatory, and technological expertise today’s eCOA market demands and patients deserve. Visit phtcorp.com for more information on PHT. Follow PHT on LinkedIn, Twitter, Google+ and YouTube.